The blinded six-month interim analysis of the PRECISE-AD phase I-B trial showed PMN310 has a strong safety profile with no ARIA-E and favorable biomarker trends, including declines in p-tau217 and MTBR-tau243. These results suggest target engagement and potential disease modification, pending confirmation in the final unblinded analysis.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.